From Yahoo Finance: 2025-05-27 15:32:00

H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $45 after the early start of the OKRA-002 trial. The novel monoclonal antibody targets IL-17A and IL-17F for psoriasis, positioning ORKA-001 and ORKA-002 to compete with existing treatments like Bimzelx.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics primarily for psoriasis and other inflammatory and immunology conditions. ORKA-001 and ORKA-002 are the company’s lead products, showing promising potential in the market.

Analyst Mitchell Kapoor believes that ORKA-001 and ORKA-002 are well-positioned to compete with existing treatments and that the current valuation of Oruka Therapeutics, Inc. (NASDAQ:ORKA) does not reflect the potential of its lead products. The early start of the OKRA-002 trial is seen as a significant milestone for the company’s clinical development timelines.

Read more: H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial